Wall Street analysts expect that Quanterix Corp (NASDAQ:QTRX) will announce earnings per share of ($0.36) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Quanterix’s earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.36). Quanterix reported earnings of ($0.42) per share during the same quarter last year, which indicates a positive year over year growth rate of 14.3%. The firm is expected to issue its next quarterly earnings results on Monday, March 16th.
On average, analysts expect that Quanterix will report full year earnings of ($1.52) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.51). For the next financial year, analysts forecast that the business will report earnings of ($1.59) per share, with EPS estimates ranging from ($1.67) to ($1.51). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Quanterix.
Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.01. Quanterix had a negative return on equity of 54.74% and a negative net margin of 75.78%. The company had revenue of $14.94 million during the quarter, compared to analysts’ expectations of $12.52 million.
In other news, Director Martin D. Madaus sold 1,600 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $22.28, for a total transaction of $35,648.00. Following the completion of the sale, the director now owns 8,149 shares in the company, valued at $181,559.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David C. Duffy sold 1,667 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.68, for a total value of $42,808.56. Insiders have sold 16,656 shares of company stock valued at $391,088 in the last 90 days. Company insiders own 30.80% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in QTRX. Gilder Gagnon Howe & Co. LLC grew its holdings in Quanterix by 11.6% during the third quarter. Gilder Gagnon Howe & Co. LLC now owns 3,422,605 shares of the company’s stock worth $75,160,000 after acquiring an additional 354,437 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Quanterix by 3.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,030,830 shares of the company’s stock worth $34,832,000 after acquiring an additional 37,869 shares during the period. BlackRock Inc. grew its holdings in Quanterix by 29.7% during the second quarter. BlackRock Inc. now owns 877,059 shares of the company’s stock worth $29,636,000 after acquiring an additional 200,999 shares during the period. Vanguard Group Inc. grew its holdings in Quanterix by 5.7% during the second quarter. Vanguard Group Inc. now owns 502,525 shares of the company’s stock worth $16,981,000 after acquiring an additional 26,894 shares during the period. Finally, Millennium Management LLC grew its holdings in Quanterix by 16.7% during the third quarter. Millennium Management LLC now owns 478,113 shares of the company’s stock worth $10,499,000 after acquiring an additional 68,351 shares during the period. Institutional investors and hedge funds own 67.50% of the company’s stock.
NASDAQ QTRX traded down $0.77 on Monday, reaching $24.14. The stock had a trading volume of 82,894 shares, compared to its average volume of 99,419. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.00 and a current ratio of 7.61. Quanterix has a 12-month low of $17.08 and a 12-month high of $36.15. The business’s 50-day moving average price is $23.36 and its 200 day moving average price is $26.38. The stock has a market cap of $704.29 million, a P/E ratio of -16.88 and a beta of 1.36.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Recommended Story: What is the Dividend Aristocrat Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.